CUBE vs RPRX · P/E 25, rev $1.07B vs P/E 15, rev $2.26B
CubeSmart (CUBE) versus Royalty Pharma Plc (RPRX) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported RPRX revenue for 2024-12-31 was $2.26B. Net income was $1.33B. Revenue was down 3.9% from 2023-12-31 to 2024-12-31. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
Not investment advice. Open the CUBE and RPRX stock pages for the full models.
Not investment advice.